Does Bristol-Myers Squibb’s new activist investor want to stall its Celgene buyout?

Analysts and investors have both raised questions about Bristol-Myers Squibb’s $74 billion Celgene buyout. And activist Starboard Value—reportedly, a new BMS shareholder—may be joining that list.